← Leaderboards
Thomas J. Smith
Control Delivery Systems, Inc.
$25,784,992
Attributed
$31,229,627
Total exposure
34
Grants
28
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,730,347 · 33
FDA$499,280 · 1
By mechanism
R44$22,326,985 · 13
R33$2,755,982 · 2
R43$2,437,196 · 13
U44$1,299,084 · 1
R61$868,774 · 1
R21$830,464 · 2
Top collaborators
- Amanda Malone9 shared
- Sarjan Shah5 shared
- John A Moss1 shared
Others in their field
Top investigators on “Drug Delivery Systems”
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Gerald Van Belle · University Of Washington$48,120,734
- David Heimbrook · Leidos Biomedical Research, Inc.$47,325,954
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$38,382,452
- Martin Friedlander · Scripps Research Institute$36,319,942
Research focus
Drug Delivery SystemsPharmaceutical PreparationsDrug KineticsSafetyClinical TrialsAnimalsResearch PersonnelInnovationPharmacologic SubstanceBaseTechnologyFda ApprovedAntiviral AgentsLeadDevicesDrug DevelopmentVaginal RingMarketingWomanIn VitroEnvironmentIn VivoPre-ClinicalChemistry
Grant awards (62)
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,000,000
R44 · FY2025 · AI · contact PI
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,025,000
R44 · FY2024 · AI · contact PI
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,025,000
R44 · FY2023 · AI · contact PI
Long-acting injectable tacrolimus for chronic immunosuppression$1,023,600
R44 · FY2023 · AI · contact PI
Long-acting injectable tacrolimus for chronic immunosuppression$1,024,014
R44 · FY2022 · AI · contact PI
Longer-acting intravaginal formulation of buprenorphine$845,335
R44 · FY2022 · DA · contact PI
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy$462,000
R33 · FY2022 · AI · contact PI
Longer-acting intravaginal formulation of buprenorphine$845,335
R44 · FY2021 · DA · contact PI
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy$460,634
R33 · FY2021 · AI · contact PI
I-Corps: Longer-acting intravaginal formulation of buprenorphine$54,916
R44 · FY2021 · DA · contact PI
IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women$1,000,000
R44 · FY2020 · AI · contact PI
IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy$999,998
R44 · FY2020 · AI · contact PI
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy$461,550
R33 · FY2020 · AI · contact PI
Longer-acting intravaginal formulation of buprenorphine$253,692
R44 · FY2020 · DA · contact PI
IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy$999,998
R44 · FY2019 · AI · contact PI
IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women$860,561
R44 · FY2019 · AI · contact PI
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy$433,812
R61 · FY2019 · AI · contact PI
IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy$434,962
R61 · FY2018 · AI · contact PI
Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women$251,190
R43 · FY2018 · AI · contact PI
Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus$766,264
U44 · FY2017 · AI · contact PI
Preclinical development of an intravaginal ring for the sustained-release of octreotide for the treatment of acromegaly.$224,881
R43 · FY2017 · HD · contact PI
Automation of GMP manufacturing of HIV microbicide rings$698,040
R44 · FY2016 · MH · contact PI
Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals$637,265
R44 · FY2016 · HD · contact PI
Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus$532,820
U44 · FY2016 · AI · contact PI
Automation of GMP manufacturing of HIV microbicide rings$447,022
R44 · FY2016 · MH · contact PI
Preclinical development of a multipurpose intravaginal ring for the prevention of HIV and unintended pregnancy$219,324
R43 · FY2016 · AI · contact PI
Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals$664,015
R44 · FY2015 · HD · contact PI
Automation of GMP manufacturing of HIV microbicide rings$337,439
R44 · FY2015 · MH · contact PI
Depot intra-articular fluticasone for the treatment of arthritis$628,279
R44 · FY2014 · AR · contact PI
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$975,223
R44 · FY2013 · AI · contact PI
Depot intra-articular fluticasone for the treatment of arthritis$563,622
R44 · FY2013 · AR · contact PI
An IVIVC system to facilitate the development of a generic Vitrasert$499,280
U01 · FY2013 · FD · contact PI
Microbicide intravaginal ring IND enabling studies$338,981
R43 · FY2013 · HD · contact PI
An intravaginal ring for real-time evaluation of adherence to topical vagina$211,862
R41 · FY2013 · AI
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$978,004
R44 · FY2012 · AI · contact PI
Intravaginal ring microbicide formulations comprising multiple anti-HIV agents$457,808
R33 · FY2012 · AI · contact PI
Intravaginal ring delivery of tenofovir and emtricitabine$300,000
R43 · FY2012 · AI · contact PI
Sustained Release intravitreal VEGFR inhibition to prevent blindness$296,405
R43 · FY2012 · EY · contact PI
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$1,000,000
R44 · FY2011 · AI · contact PI
Sustained Release Depot Olanzapine$537,375
R44 · FY2011 · MH · contact PI
Intravaginal ring microbicide formulations comprising multiple anti-HIV agents$464,692
R33 · FY2011 · AI · contact PI
Depot calcineurin inhibitors to prevent graft rejection$839,479
R44 · FY2010 · AI · contact PI
Sustained Release Depot Olanzapine$536,519
R44 · FY2010 · MH · contact PI
Intravaginal ring microbicide formulations comprising multiple anti-HIV agents$449,298
R33 · FY2010 · AI · contact PI
Vaginal ring formulation of tenofovir microbicide$257,925
R21 · FY2010 · AI · contact PI
Depot calcineurin inhibitors to prevent graft rejection$491,344
R44 · FY2009 · AI · contact PI
Intravaginal ring microbicide formulations comprising multiple anti-HIV agents$236,769
R21 · FY2009 · AI · contact PI
Sustained release acyclovir for prophylaxis of genital herpes$223,952
R43 · FY2009 · AI · contact PI
Vaginal ring formulation of tenofovir microbicide$153,500
R21 · FY2009 · AI · contact PI
Sustained Release Apomrophine for Parkinson's Disease$369,406
R44 · FY2008 · NS · contact PI
Intravaginal ring microbicide formulations comprising multiple anti-HIV agents$182,270
R21 · FY2008 · AI · contact PI
Sustained release depot pre-exposure prophylaxis in breast feeding populations$383,602
R44 · FY2007 · HD · contact PI
Sustained Release Apomrophine for Parkinson's Disease$326,938
R44 · FY2007 · NS · contact PI
Sustained release calcineurin inhibitors for the prevention of graft rejection$99,120
R43 · FY2007 · AI · contact PI
Sustained release depot pre-exposure prophylaxis in breast feeding populations$391,705
R44 · FY2006 · HD · contact PI
Sustained Release Intravitreal Corticosteroid Injections$99,368
R43 · FY2006 · EY · contact PI
Intra-articular sustained release steroid injections$100,000
R43 · FY2005 · AR
Continuous Dopaminergic Stimulation: Parkinson's Disease$100,000
R43 · FY2005 · NS
Prevention of HIV Transmission in Breast Feeding Populations$83,975
R43 · FY2005 · HD
Sustained Release Olanzapine$100,000
R43 · FY2004 · MH
CYCLOSPORINE IMPLANT FOR CORNEAL GRAFT REJECTION$296,944
R44 · FY2001 · EY
CYCLOSPORINE IMPLANT FOR CORNEAL GRAFT REJECTION$267,315
R44 · FY2000 · EY